Natural small-molecules reverse Xeroderma Pigmentosum Complementation Group C (XPC) deficient-mediated drug-resistance in renal cell carcinoma

Background: Renal cancer is insensitive to radiotherapy or most chemotherapies. While the loss of the XPC gene was correlated with drug resistance in colon cancer, the expression of XPC and its role in the drug resistance of renal cancer have not yet been elucidated. With the fact that natural small -molecules have been adopted in combinational therapy with classical chemotherapeutic agents to increase the drug sensitivity and reduce adverse effects, the use of herbal compounds to tackle drug -resistance in renal cancer is advocated. Purpose: To correlate the role of XPC gene deficiency to drug -resistance in renal cancer, and to identify natural small -molecules that can reverse drug -resistance in renal cancer via up -regulation of XPC. Methods: IHC was adopted to analyze the XPC expression in human tumor and adjacent tissues. Clinical data extracted from The Cancer Genome Atlas (TCGA) database were further analysed to determine the relationship between XPC gene expression and tumor staging of renal cancer. Two types of XPC-KD renal cancer cell models were established to investigate the drug -resistant phenotype and screen XPC gene enhancers from 134 natural small -molecules derived from herbal plants. Furthermore, the identified XPC enhancers were verified in single or in combination with FDA -approved chemotherapy drugs for reversing drug -resistance in renal cancer using MTT cytotoxicity assay. Drug resistance gene profiling, ROS detection assay, immunocytochemistry and cell live -dead imaging assay were adopted to characterize the XPC-related drug resistant mechanism. Results: XPC gene expression was significantly reduced in renal cancer tissue compared with its adjacent tissue. Clinical analysis of TCGA database also identified the downregulated level of XPC gene in renal tumor tissue of stage IV patients with cancer metastasis, which was also correlated with their lower survival rate. 6 natural small -molecules derived from herbal plants including tectorigenin, pinostilbene, d-pinitol, polygalasaponin F, atractylenolide III and astragaloside II significantly enhanced XPC expression in two renal cancer cell types. Combinational treatment of the identified natural compound with the treatment of FDA -approved drug, further confirmed the up -regulation of XPC gene expression can sensitize the two types of XPC-KD drug -resistant renal cancer cells towards the FDA -approved drugs. Mechanistic study confirmed that GSTP1/ROS axis was activated in drug resistant XPC-KD renal cancer cells. Conclusion: XPC gene deficiency was identified in patient renal tumor samples, and knockdown of the XPC gene was correlated with a drug -resistant phenotype in renal cancer cells via activation of the GSTP1/ROS axis. The 6 identified natural small molecules were confirmed to have drug sensitizing effects via upregulation of the XPC gene. Therefore, the identified active natural small molecules may work as an adjuvant therapy for circumventing the drug -resistant phenotype in renal cancer via enhancement of XPC expression.